Paloma Partners Management Co decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 39.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,511 shares of the biopharmaceutical company’s stock after selling 10,027 shares during the period. Paloma Partners Management Co’s holdings in Alnylam Pharmaceuticals were worth $795,000 as of its most recent filing with the SEC.
Other hedge funds also recently added to or reduced their stakes in the company. First Manhattan Co. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $135,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $148,000. Westpac Banking Corp bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $202,000. Prudential Financial Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $215,000. Finally, Nisa Investment Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $256,000. Institutional investors own 89.27% of the company’s stock.
Alnylam Pharmaceuticals, Inc. (ALNY) opened at 78.97 on Wednesday. The firm’s market cap is $6.81 billion. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $86.92. The firm has a 50-day moving average price of $73.05 and a 200 day moving average price of $53.57.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The company had revenue of $19 million for the quarter, compared to analyst estimates of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The company’s revenue was up 160.3% on a year-over-year basis. During the same quarter last year, the business earned ($1.21) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.26) EPS for the current year.
Several analysts have recently issued reports on ALNY shares. FBR & Co reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, March 20th. Chardan Capital set a $95.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price target for the company. in a research note on Monday, May 15th. Piper Jaffray Companies set a $118.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. Finally, Ladenburg Thalmann Financial Services set a $80.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 17th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.13.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares in the company, valued at $393,750. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Akshay Vaishnaw sold 43,750 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the sale, the senior vice president now owns 43,047 shares of the company’s stock, valued at $2,798,055. The disclosure for this sale can be found here. Insiders have sold 64,125 shares of company stock valued at $4,325,000 over the last 90 days. Company insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.